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ResearchMicroRNA-184 inhibits neuroblastoma cell survival 
through targeting the serine/threonine kinase 
AKT2
Niamh H Foley†1,2, Isabella M Bray†1,2, Amanda Tivnan1,2, Kenneth Bryan1,2, Derek M Murphy1,2, Patrick G Buckley1,2, 
Jacqueline Ryan1,2, Anne O'Meara3, Maureen O'Sullivan2,4 and Raymond L Stallings*1,2
Abstract
Background: Neuroblastoma is a paediatric cancer of the sympathetic nervous system. The single most important 
genetic indicator of poor clinical outcome is amplification of the MYCN transcription factor. One of many down-stream 
MYCN targets is miR-184, which is either directly or indirectly repressed by this transcription factor, possibly due to its 
pro-apoptotic effects when ectopically over-expressed in neuroblastoma cells. The purpose of this study was to 
elucidate the molecular mechanism by which miR-184 conveys pro-apoptotic effects.
Results: We demonstrate that the knock-down of endogenous miR-184 has the opposite effect of ectopic up-
regulation, leading to enhanced neuroblastoma cell numbers. As a mechanism of how miR-184 causes apoptosis 
when over-expressed, and increased cell numbers when inhibited, we demonstrate direct targeting and degradation 
of AKT2, a major downstream effector of the phosphatidylinositol 3-kinase (PI3K) pathway, one of the most potent pro-
survival pathways in cancer. The pro-apoptotic effects of miR-184 ectopic over-expression in neuroblastoma cell lines is 
reproduced by siRNA inhibition of AKT2, while a positive effect on cell numbers similar to that obtained by the knock-
down of endogenous miR-184 can be achieved by ectopic up-regulation of AKT2. Moreover, co-transfection of miR-184 
with an AKT2 expression vector lacking the miR-184 target site in the 3'UTR rescues cells from the pro-apoptotic effects 
of miR-184.
Conclusions: MYCN contributes to tumorigenesis, in part, by repressing miR-184, leading to increased levels of AKT2, a 
direct target of miR-184. Thus, two important genes with positive effects on cell growth and survival, MYCN and AKT2, 
can be linked into a common genetic pathway through the actions of miR-184. As an inhibitor of AKT2, miR-184 could 
be of potential benefit in miRNA mediated therapeutics of MYCN amplified neuroblastoma and other forms of cancer.
Introduction
Neuroblastoma is a paediatric cancer of the sympathetic
nervous system and accounts for approximately 15% of all
childhood cancer related deaths. The disease has a highly
varied clinical outcome, some tumours can spontane-
ously regress without treatment, while others can prog-
ress and lead to the death of the patient in spite of
intensive multi-modal chemotherapy. Amplification of
the MYCN transcription factor is the single most impor-
tant prognostic indicator of poor patient survival and
determination of genomic MYCN copy number status
plays a major role in the stratification of patients for
treatment [1]. This oncogenic transcription factor is
responsible for the dysregulation of numerous genes and
genetic pathways in neuroblastoma [2], and more
recently it has become apparent that MYCN is also
responsible for the dysregulation of microRNA [3-6].
MicroRNAs are a class of small (19-25 nt) noncoding
regulatory RNAs that regulate gene expression through
their binding to sites within the 3'UTR of an mRNA tar-
get gene, causing either mRNA degradation or transla-
tional inhibition [7]. These small non-coding molecules
have a major role in the control of many normal cellular
processes, such as cell division [8,9] or differentiation
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[10], and their dysregulation plays a major role in many
forms of cancer [11], including neuroblastoma, as shown
by expression profiling and functional studies [3-6,12-19].
Through miRNA expression profiling of different
genetic subtypes of neuroblastoma, Chen and Stallings
[3] and others [5,19,20] previously demonstrated that
several miRNAs are differentially expressed in these
tumors, particularly in regard to MYCN amplified
(MNA) versus non-MNA tumor subtypes. One of the
miRNAs that was expressed at lower levels in the MNA
tumors relative to non-MNA tumors was miR-184, which
was demonstrated to cause a decrease in cell numbers
and an increase in caspase mediated apoptosis when
transiently transfected into both MNA and non-MNA
neuroblastoma cell lines. In this report, we identify the
important molecular mechanism by which miR-184
exerts its negative effects on neuroblastoma cell survival,
which involves the direct targeting of the 3'UTR of AKT2
mRNA, a major downstream effector of the phosphati-
dylinositol 3-kinase (PI3K) pathway, an important pro-
survival pathway in cancer [21-23]. Thus, MYCN causes
enhanced tumorgenicity, in part, through repressing a
miRNA that targets this important pro-survival gene,
never previously associated with neuroblastoma patho-
genesis.
Materials and methods
Human Tissue Samples
Neuroblastoma tumour samples were obtained from
patients at Our Lady's Hospital for Sick Children in
Crumlin, Ireland or through the Children's Oncology
Group (USA) and have been previously described in
aCGH [24], mRNA [25] and miRNA [3] profiling studies.
Cell Culture
Kelly and SK-N-AS cell lines were purchased from the
European Collection of Animal Cell Cultures (Porton
Down, United Kingdom). SHEP-TET21 cells were
obtained from Dr. Louis Chesler with permission of Prof.
Manfred Schwab [26]. Kelly cells and SHEP-TET21 cells
were grown in RPMI 1640 supplemented with 10% fetal
bovine serum, 2 mM Glutamine and 2 mM penicillin and
streptomycin (GIBCO). SK-N-AS cells were cultured in
EMEM (GIBCO) supplemented with 10% fetal bovine
serum, glutamine and penicillin and streptomycin.
Transfections
Pre-miR™ and Anti-miR™ to miR-184 and negative con-
trol 1 (a scrambled oligonucleotide) were obtained from
Ambion (Austin, Texas). Short interfering (si)RNAs tar-
geting AKT2 were obtained from Applied Biosystems
(Foster City, CA). Three different siRNAs against AKT2
were chosen (s1215 sense CAACUUCUCCGUAGCA-
GAAtt, anti-sense UUCUGCUACGGAGAAGUUGtt,
s1217 sense strand UGACUUCGACUA UCUCAAAtt
and anti sense strand UUUGAGAUAGUCGAAGUCAtt)
(s228853 sense strand ACAACUUCUCCGUAGCAGAtt
and anti sense strand UCUGCUACGGAGAAGUU-
GUtt).
The Pre-miR™ and Anti-miR™ to miR-184, negative
control 1 and the siRNAs to AKT2 were introduced into
the cells by reverse transfection using the transfection
agent siPORT™ NeoFX™(Ambion). Cell culture media was
changed after 8 hours to remove the transfection reagent
in an attempt to avoid toxicity which may be caused by
NeoFX™. Total RNA/miRNA was extracted 24, 48 and 72
hours after transfection using RNeasy Kit/mirNeasy© kit
(Qiagen, UK).
Stem-loop Reverse transcription and Real-time PCR
Reverse transcription was carried out using 50 ng of total
RNA with the primer specific for miR-184 and the Taq-
Man microRNA reverse transcription kit (Applied bio-
systems). qPCR was carried out on the 7900 HT Fast
Realtime System (Applied Biosystems). RNU66, a small
RNA encoded in the intron of RPL5 (chr1:93,018,360-
93,018,429; 1p22.1), was used for normalization in
miRNA studies and RPLPO ribosomal protein was used
for normalization in gene expression studies (chr12:
119,118,300-119,124; 12q24.2). A relative fold change in
expression of the target miRNA/gene transcript was
determined using the comparative cycle threshold
method (2-ΔΔCT).
Significance testing for Tumour Subtypes
The significance of miRNA differential expression over
tumour sub-types was evaluated by assigning P-values
based on the non-parametric Mann-Whitney test.
Cloning the Precusor miRNA-184
The stem loop precursor sequence of miR184 was cloned
into the pcDNA6.2-GW/EmGFP expression vector
(BLOCK-iT Pol II miR RNAi Expression Vector kit, Invit-
rogen). The following oligonucleotides were designed
which encode the sense and antisense strands of the pre-
miR184 sequence. These oligonucleotides include the
appropriate 5' and 3' overhangs to facilitate cloning into
the linearised pcDNA6.2-GW/EmGFP vector (supplied
within the BLOCK-iT kit, Invitrogen).
Pre-miR184 Sense strand:
TGCTGCCAGTCACGTCCCCTTATCACTTTTCCA
GCCAGCTTTGTGACTGTAAGTGTTGGCAGGA-
GAACTGATAAGGGTAGGTGATTGA
Pre-miR184 Antisense strand:
CCTGTCAATCACCTACCCTTATCAGTTCTCCTG
CCAACACTTACAGTCACAAAGCTGGCTG-
GAAAAGTGATAAGGGGACGTGACTGGC
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The pcDNA6.2-GW/EmGFP-miRNA-184 construct or
the control construct (pcDNA6.2-GW/EmGFP-miRneg-
ative control, Invitrogen) was transfected into Kelly and
SK-N-AS cells using lipofectamine 2000 (Invitrogen,
Carslbad) according to manufacturers instructions.
Quantitative real-time PCR and fluorescent microscopy
were carried out to determine efficient transfection and
transcription of the vector.
AKT2 Expression Vector
The expression vector pcDNA 3 containing AKT2 was
obtained from Prof. Joe Testa (Fox Chase Cancer Centre,
Philadelphia) [27]. 1 μg of the vector or the control empty
vector was transfected into Kelly and SK-N-AS cells using
Lipofectamine 2000.
Apoptosis Assays
Apoptosis was demonstrated by annexin-V staining and
propidium iodide (PI) exclusion using the FITC Annexin-
V Apoptosis Detection Kit I (BD Pharmingen, San Diego,
CA, USA). Briefly, adherent and supernatant Kelly cells
were collected, washed twice in cold PBS, and resus-
pended in 1× Annexin-V binding buffer at a concentra-
tion of 1 × 106 cells/ml. An aliquot of 100 μl of suspension
(1 × 105 cells) was stained with 5 μl Annexin-V-FITC and
5 μl PI, and incubated for 15 minutes at room tempera-
ture in the dark. Binding buffer (400 ul) was added and
cells acquired (10,000 cells) immediately using a BD LSR
II flow cytometer (Becton Dickinson, San Jose, CA, USA)
and analysed using BD FACSDiva 4.0 Software. Experi-
ments were performed in multiples to qualify apoptosis
by phosphatidylserine (PS) externalization.
Cell Death was also evaluated using the 3/7 Caspase
detection kit from Promega (Madison, WI). Neuroblas-
toma experimental cells were plated in quadruplicate in
96-well plates. 72 hours after transfection, 10 ul of cas-
pase 3/7 was added to each well. Samples were read after
1 hr of incubation with the caspase substrate on a Viktor
Microplate luminometer (Molecular Devices, Sunnyvale,
CA).
Growth Curve
For cell number assays, cells were set up in triplicate in 6
well plates. Cells were seeded at equal densities of 3 × 104
cells per well. When carrying out transfections using the
microRNA mimics or anti-miRs (as described above)
each time point was set up with a non-transfected (with
transfection reagent) and a scrambled oligonucleotide
control (negative 1). Cells were trypsinised from 6 well
plates at 24, 48 and 72 hour time points, and re-sus-
pended in 1 ml of media. A haemocytometer was used to
count cell numbers. Counts from triplicate wells were
averaged.
Western Blot
Total protein was isolated from cells using a radioimmu-
noprecipitation assay (RIPA) lysis buffer (Sigma). Protein
concentration was measured using the BCA assay from
Millipore. Proteins were fractionated on 10% polyacryl-
amide gels, and blotted onto nitrocellulose membrane.
The membrane was probed with the Anti-AKT2 Anti-
body (Millipore) or anti-MYCN (Abcam), anti β-Actin
from (Abcam) or anti GAPDH (abcam) (used for loading
controls). Signal was detected using Immoblion Western
(Millipore).
Luciferase Reporter
A 76nt long region of the 3'UTR of AKT2 containing the
predicted miR-184 binding site (underlined) was ligated
into the pMiR-Reporter vector (Ambion) 3' of the
luciferase
gene:5'CTAGTCCTCTGTGTGCGATGTTGTTATCTG
ACAGTTCTCCGTCCCTACTGGCCTTTCTC-
CTCGTCTTCGCTCAGCA 3'
As a negative control, three mutations (lower case)
were introduced into the seed region of miR-184 binding
site of this sequence:
5'CTAGTCCTCTGTGTGCGATGTTGTTATCTGAC
AGTTCTtCaaCCCTACTGGCCTTTCTCCTCGTCT-
TCGCTCAGCA 3'
KELLY cells were plated at 8 × 104 in 12 well format.
After 24 hrs the pMir-Reporter containing the AKT2
binding site for miR-184 or the mutated AKT2 binding
site were co-transfected with either the pre-miR-184
mimic or a scrambled negative control sequence using
Lipofectamie 2000. All experiments were also co-trans-
fected with the pmiR-Report β-galactosidase vector as a
control for transfection efficiency and normalization.
Luciferase activity was measured by One-Glo luciferase
assay (Promega) according to manufactures instructions
after 24 hours on the Viktor Plate Reader.
Results
MiR-184 expression is inversely related to MYCN levels
In order to experimentally determine that MYCN levels
influence quantities of miR-184, we examined miR-184
expression in the SH-EP TET21 neuroblastoma cell line
containing a MYCN construct which is repressible by
doxycycline. As demonstrated by qPCR and Western
blotting, addition of doxycycline to the cell culture caused
a dramatic reduction in both MYCN mRNA and protein
levels (Additional File 1a and 1b). MYCN depleted SH-EP
cells had an 8 fold increase in MiR-184 levels (Additional
File 1c), indicating that MYCN either directly or indi-
rectly suppresses miR-184 transcription, consistent with
our earlier expression profiling studies of primary tumors
[3].
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Biological effects of MiR-184 ectopic up-regulation and 
endogenous down-regulation
It was previously reported that transfection of miR-184
mimics into neuroblastoma cell lines causes a decrease in
cell numbers and increase in apoptosis in neuroblastoma
cell lines [3]. Here, we first assessed whether the recipro-
cal experiment of knocking down endogenous miR-184
in Kelly and SK-N-AS cell lines following transfection
with an anti-miR-184 also has a detectable biological
effect. As illustrated in Figure 1a and 1b, the inhibition of
miR-184 results in a reproducible and statistically signifi-
cant increase in cell numbers (~1.6 fold in Kelly; p <
0.0001; and 1.3 fold in SK-N-AS; p < 0.0001) (Figure 1a
and 1b). In addition, we also determined that ectopic
over-expression of miR-184 at physiological levels using
an expression plasmid has similar biological effects on
Kelly and SK-N-AS cells as the mature miR-184 mimics
which were introduced at supra-physiological levels
(Additional File 2a-g). The molecular mechanism by
which miR-184 exerts effects on cell numbers and apop-
tosis of neuroblastoma cells, however, is unknown.
MiR-184 targets the AKT2 mRNA 3' UTR
An examination of the Sanger microcosm database http:/
/microrna.sanger.ac.uk/sequences/ indicated that miR-
184 has a very large number of computationally predicted
mRNA targets. Among the top 3% (n = 30) of miR-184
predicted targets was the 3'UTR of AKT2, which had a
high level of sequence identity with the miR-184 seed
region, a 13 base pair match (Figure 2a). We focused our
studies on AKT2 as a potential miR-184 target given that
this was the only gene in the top 3% whose function
might account for the apoptotic phenotype induced by
miR-184. AKT2 is a well documented pro-survival pro-
teinFor an initial assessment of whether AKT2 mRNA
levels and miR-184 levels might be inversely related,
qPCR analysis of AKT2 mRNA was carried out on 10
tumors with low miR-184 and 10 with high levels. As
illustrated in Figure 2b, AKT2 mRNA levels are signifi-
cantly lower in tumors with higher miR-184 (P < 0.002).
As one might expect, AKT2 was expressed at higher lev-
els in MNA tumors relative to non-MNA tumors (P <
0.035), as MYCN suppresses miR-184 transcript quanti-
ties (Figure 2c). An inverse relationship between miR-184
and AKT2 mRNA levels was also determined to exist in
neuroblastoma cell lines (Figure 3a and 3b). Levels of
AKT2 protein corresponded to the levels of mRNA in the
cell lines (Figure 3c).
To confirm that AKT2 was indeed regulated by miR-
184 in neuroblastoma, the miR-184 mimic and the anti-
miR-184 were individually transfected into Kelly and SK-
N-AS cell lines. A significant decrease of AKT2 mRNA
was observed over three time points (24, 48 and 72 hrs)
following transfection of miR-184 mimics into Kelly (P =
0.004)(Figure 4a) and SK-N-AS (P = 0.003)(Figure 4b),
and conversely, the suppression of miR-184 using the
anti-mir-184 caused an increase in mRNA for AKT2
across all time points in both cell lines (P = 0.009 and 0.01
respectively). These results were also observed at protein
level (Figure 4c). MiR-184 is not predicted to target the
3'UTRs of related AKT family members, AKT1 nor
AKT3. Consistent with expectations, AKT1 mRNA levels
remained constant when miR-184 was transfected into
Kelly and SK-N-AS (Additional File 3a), while AKT3
mRNA was undetectable in both cell lines by TaqMan
qPCR.
The effect of miR-184 on AKT2 levels appears to be a
direct effect of miR-184 targeting AKT2 mRNA, since co-
transfection of a pMir-Reporter containing the AKT2
binding site for miR-184 and mature miR-184 mimics sig-
nificantly (p < 0.003) diminished luciferase activity while
co-transfection of the reporter with a negative control
Figure 1 Growth curves for Kelly (A) and SK-N-AS (B) following transfection with the anti-miR-184 (×3 biological replicates). A scrambled 
anti-miR was used as negative control.
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oligonucleotide had no effect (Figure 4d). A three base
pair mutation introduced into the seed region of the miR-
184 binding site in the AKT2 3' UTR completely abol-
ished the ability of mature miR-184 mimics to affect
luciferase activity.
The phenotypic effects of miR-184 can be attributed to 
targeting AKT2
MiR-184 has many computationally predicted targets, so
in order to determine if the anti-proliferative effects of
miR-184 could be attributable to targeting AKT2, we
transfected both Kelly and SK-N-AS neuroblastoma cell
lines with three different siRNAs to AKT2 and examined
the effects on the rate of accumulation of cell numbers.
AKT2 mRNA knockdown ranged from 68 to 98% by 48
hrs, depending on the siRNA (Additional File 4a and 4c),
with AKT2 protein being proportionally reduced (Addi-
tional File 4b and 4d). Both cell lines exhibited a marked
decline in cell numbers for each siRNA relative to the
negative control (Figure 5a and 5b), along with a highly
significant increase (3.9 fold; P < 0.0001) in the late apop-
totic cell fraction assessed by FACs analysis of an annexin
V staining assay (Figure 6a and 6b). A statistically signifi-
cant increase in caspase 3/7 activation in both Kelly and
SK-N-AS cells following siRNA mediated AKT2 knock
down also occurred (Figure 6c and 6d). Consistent with
expectations, AKT1 mRNA levels remained constant
when AKT2 siRNA was transfected into the cell lines
(Additional File 3b).
To demonstrate that the increase in cell numbers that
occurred following miR-184 knockdown resulted specifi-
Figure 2 (A) Predicted alignment of miR-184 to the mRNA 3'UTR region of AKT2, as predicted by the Sanger miR Registry. (B) AKT2 mRNA 
levels were significantly different (p < 0.002) between tumours with high miR-184 levels (predominantly MNA tumors)(n = 10) and tumours with low 
miR-184 levels (predominantly non-MNA)(n = 9). AKT2 mRNA levels were also significantly different (p < 0.035) between tumours with MNA (n = 10) 
versus non-MNA (n = 9).
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cally from AKT2 up-regulation, we transfected the
pcDNA3-AKT2 plasmid into Kelly neuroblastoma cells.
This resulted in a 5 to 22 fold increase in AKT2 mRNA
levels, and a 30% increase in cell numbers by the 72 hr
time point relative to the negative control (p = 0.006).
(Figure 5c). Since the pcDNA3-AKT2 construct lacks the
miR-184 binding site in the 3' UTR, we also co-trans-
fected pcDNA3-AKT2 along with the miR-184 mimics to
determine if ectopic up-regulation of AKT2 could rescue
Kelly cells from the anti-proliferative effects of miR-184.
As illustrated in Figure 5c, the numbers of cells accumu-
lated over 72 hours for Kelly cells co-transfected with
pcDNA3-AKT2 and miR-184 was not statistically differ-
ent to that of Kelly cells transfected with a negative con-
trol oligonucleotide and the pcDNA3 empty vector.
However, this co-transfection with pcDNA3-AKT2 and
miR-184 mimics yielded a cell accumulation rate that was
significantly higher then cells transfected with miR-184
mimics (p <0.003) or miR-184 mimics and pc-DNA3.1
empty vector (p <0.003), indicating that ectopic AKT2
lacking a miR-184 binding site can rescue the cells from
ectopic miR-184 up-regulation (Figure 5c). As illustrated
in Additional File 5, RT-qPCR analysis of AKT2 mRNA
indicated that there were statistically significant (p < 0.01)
differences in AKT2 mRNA levels in each of the trans-
fected cell populations at each time point, consistent with
expectations. From all of the above experiments, we con-
clude that the phenotypic effects of miR-184, at least to a
large extent, can be attributed to the targeting and reduc-
tion of AKT2.
Discussion
This study identifies AKT2 as an important pro-survival
gene in neuroblastoma and our results further demon-
strate that MYCN indirectly regulates AKT2 through
miR-184. It is unknown whether MYCN directly or indi-
rectly suppresses miR-184 expression. There are two
DNA sequence motifs, GGCATG and CCCGTG,
reported to bind to MYCN at the MCM4 and MCM5 loci
[28], approximately 2.6 Kb upstream of the predicted
miR-184 start site, so it is possible that the suppression of
miR-184 is a direct effect of MYCN binding. Examination
of our MYCN chromatin immunoprecipitation data, as
detailed in Murphy et al [29], indicates that MYCN binds
Figure 3 (A) RT-qPCR analysis of miR-184 in four neuroblastoma cell lines. RNU66 was used as an endogenous control and expression levels are 
relative to SH-SY5Y, set as 1.0. AKT2 mRNA (B) and protein (C) levels in the same four neuroblastoma cell lines (SK-N-AS, SK-N-BE, Kelly, SH-SY5Y). Actin 
was used as an endogenous loading control for the western blot, while RPLPO was used as endogenous control for RT-qPCR, all values are relative to 
SK-N-AS. Note that AKT2 mRNA levels show an inverse relationship to the endogenous miR-184 levels.
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weakly to this site, but whether this binding actually has a
regulatory effect requires further experimental studies.
Regardless of whether the effect of MYCN on miR-184
transcript levels is direct or indirect, we conclude that
MYCN provides a tumourigenic effect, in part, by pro-
tecting AKT2 mRNA from degradation by miR-184, per-
mitting this important pathway to remain functional.
Although miR-184 is predicted to target several hun-
dred genes, several lines of evidence indicate that the tar-
geting of AKT2 mRNA by itself can fully account for the
observed apoptotic phenotype. First, siRNA mediated
inhibition of AKT2 in Kelly and SK-N-AS cells induces a
level of apoptosis that is comparable to miR-184 ectopic
up-regulation. Second, ectopic up-regulation of AKT2
causes an increase in cell numbers similar to that
observed following miR-184 knock-down, and the effects
of ectopic miR-184 up-regulation are abrogated by ecto-
pic over-expression of an AKT2 expression plasmid lack-
ing the miR-184 binding site. We can not rule out the
possibility that the targeting of other genes by miR-184
has altered the phenotypes of these cells in some unde-
tectable manner, only that miR-184 targeting of AKT2
fully accounts for the pro-apoptotic effects.
AKT2 is a homolog of the v-akt oncogene, a protein
serine/threonine kinase pro-survival protein, which is
member of the AKT family of proteins (AKT1, 2 and 3)
that are activated by the phosphatidylinositol 3' kinase
pathway [22]. The phosphatidylinositol 3' kinase (PI3K)
pathway is one of the most potent pro-survival pathways
in cancer [21]. Activation of the AKT pathway through
phosphorylation of serine or threonine is associated with
poor clinical outcome in neuroblastoma, as demon-
Figure 4 Relative AKT2 mRNA levels following transfection of miR-184 mimics (pre-miR-184), anti-miR-184, or a scrambled oligo (NC) into 
(A) Kelly and (B) SK-N-AS cells at 24, 48 and 72 hrs after transfection. RT-qPCR results were normalised to RPLPO ribosomal protein and are relative 
to the negative control at 24 hrs. Western Blot (C) representing protein levels of AKT2 in Kelly cells 72 hrs after transfection with the miR-184 mimics, 
a negative control oligo, or anti-miR-184. β-Actin was used for the endogenous control. (D) pMir-Reporter containing the AKT2 binding site for miR-
184 in the 3' UTR region of the luciferase gene co-transfected into Kelly cells with a scrambled negative control oligonucleotide (left) or mature miR-
184 mimic (middle). The right bar shows the result of co-transfection with the pMir-Reporter containing the mutated AKT2 binding site for miR-184 
co-transfected into Kelly cells with mature miR-184 mimic. Luciferase values were normalized to B-galactosidase on a second plasmid that was co-
transfected into each cell line and all values are relative to the negative control (left).
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strated through immunohistochemical staining of tissue
arrays with an antibody that co-recognizes all three AKT
family members [30]. In addition, inhibition of AKT acti-
vation can prevent BDNF mediated protection of neuro-
blastoma cells from chemotherapy induced apoptosis
[31]. Our results indicate that the AKT2 isoform expres-
sion levels are critical for neuroblastoma cell survival
even in the absence of chemotherapeutic compounds.
The other isoform which is expressed at high levels in
neuroblastoma cell lines, AKT1, does not possess a miR-
184 target site, remains constant in all of our experi-
ments, and does not rescue the cells from the effects of
miR-184 over-expression. This is consistent with findings
that AKT2 does not share complementary functions with
AKT1 regarding cell invasiveness and survival in other
forms of cancer [32,33].
The deregulation of the AKT signalling pathway has
been associated with numerous other cancers including
glioblastoma, breast, prostate and lung [21]. The activa-
tion of this pathway has been associated with a more
aggressive phenotype, resistance to treatment [34], and
poor outcome in a large number of cancers [21]. There is
still little known about the specific role of each of the
three AKT isoforms, however, consistent with our result
in neuroblastoma, AKT2 is emerging as one of the more
important isoforms with respect to cancer. Over-expres-
sion of AKT2 kinase is frequently observed in ovarian
cancer [35], breast cancer [36], and approximately 32% of
pancreatic tumours [37]. In addition, AKT2 down-regu-
lation sensitised ovarian cancer cells to paclitaxel induced
apoptosis and indicated that AKT2 may have a more
important role in drug resistance than other members of
the AKT family [38]. AKT2 was also shown to reduce
sensitivity to the chemotherapeutic agent, cisplatin, by
regulating XIAP, an inhibitor of execution of caspase 3
[39]. Moro et al (2009) et al recently demonstrated that
AKT2 and not AKT1 or AKT3 is activated in prostate
cancer cells in response to oxidative stress, resulting in
Figure 5 (A) Growth curves following transfection with each AKT2 siRNA and negative control for (A) Kelly (p values for each siRNA ranged 
from 0.01 to 0.03) and (B) SK-N-AS (p values for each siRNA ranged from 0.007 to 0.03). Growth curves (C) for Kelly cells following transfection 
with various combinations of AKT2 expression vector, empty vector, miR-184 mimics or negative control (NC) oligonucleotides. The highest number 
of cells was produced by either the AKT2 expression vector alone or in combination with a negative control oligonucleotide. These cells had both 
endogenous and ectopic AKT2 (Additional File 5). Co-transfection with the AKT2 expression plasmid (lacking the miR-184 target site) and miR-184 mim-
ics yielded a cell number curve that was not statistically different from co-transfection with a negative control oligonucleotide and the empty expres-
sion vector. The former cell population had ectopic but not endogenous AKT2 activity, while the latter cell population had endogenous, but no ectopic 
AKT2. Both of these cell number curves were significantly different from the other curves (p < 0.003). Transfection of miR-184 mimics by themselves 
or in combination with the empty vector significantly impacted cell growth, as these cells had no ectopic AKT2 and endogenous AKT2 was inhibited.
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enhanced cell migration and cell survival. Finally, AKT2
also has been reported to be directly implicated in cell
migration and invasiveness of glioblastoma [40].
There is presently not very much known about miR-
184 involvement in cancer. It was reported to be up-regu-
lated in squamous cell carcinoma (SCC) of the tongue,
and suppression of this miRNA in SCC cell lines showed
reduced cell numbers and an increase in apoptosis, sug-
gesting an anti-apoptotic role for mir-184 [41]. However,
this result seems contradictory to another paper pub-
lished by Yu et al (2008) where miR-184 appears to have a
tumor suppressive effect in SCC cell lines. Yu et al (2008)
showed that miR-205 targets SHIP2, a protein that causes
a reduction in activated phosphorylated AKT, but not in
total AKT amounts. Thus, miR-205, which is elevated in
aggressive SCC, is acting oncogenically by targeting
SHIP2, allowing AKT activation. They further report that
miR-184 antagonizes miR-205, so in this sense, miR-184
is acting as a tumor suppressor. The effects of ectopic
miR-184 over-expression on AKT mRNA or protein lev-
els was not examined by Yu et al (2008), and this was the
first report of a microRNA interfering with the action of
another miRNA. Our results indicating that miR-184 acts
in a tumor suppressive manner in neuroblastoma does
not shed further light upon these seemingly contradic-
tory reports, as the role of any miRNA in cancer is likely
to be cell context dependent.
Finally, a number of studies have sought to identify
small molecule inhibitors of AKT family members for
cancer therapy [42,43]. MiR-184, which targets the AKT2
mRNA, is a naturally occurring inhibitor of this protein,
and has potential value in miRNA mediated therapeutics
for any form of cancer dependent on AKT2.
Figure 6 FACs analysis of annexin V staining in Kelly cells. (A) transfection with negative control oligonucleotide and (B) siRNA mediated knock 
down of AKT2 using siRNA. Cells were harvested for detection of externalised annexin V (apoptotic cells) and PI staining of DNA (necrotic cells). Double-
stained cells (upper right quadrant) indicate cells in late apoptosis. The resultant increase in apoptosis caused by siRNA inhibition of AKT2 was highly 
significant (P < 0.0001). Analysis of caspase 3/7 activity in Kelly (C) and SK-N-AS (D) cells following siRNA knockdown of AKT2 relative to negative control 
(NC).
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